Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $20.25 Average PT from Analysts

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.80.

A number of equities analysts have commented on the stock. Robert W. Baird reduced their price objective on shares of Contineum Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. JonesTrading decreased their price target on shares of Contineum Therapeutics from $26.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Royal Bank Of Canada upped their price target on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, July 31st.

Hedge Funds Weigh In On Contineum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CTNM. Seven Fleet Capital Management LP increased its stake in shares of Contineum Therapeutics by 123.8% during the second quarter. Seven Fleet Capital Management LP now owns 60,541 shares of the company’s stock worth $992,000 after purchasing an additional 33,487 shares during the period. Wellington Management Group LLP boosted its stake in Contineum Therapeutics by 171.2% in the 2nd quarter. Wellington Management Group LLP now owns 150,797 shares of the company’s stock valued at $2,472,000 after purchasing an additional 95,188 shares during the period. Bank of America Corp DE boosted its stake in Contineum Therapeutics by 411.9% in the 1st quarter. Bank of America Corp DE now owns 47,449 shares of the company’s stock valued at $620,000 after purchasing an additional 38,180 shares during the period. Janus Henderson Group PLC grew its holdings in Contineum Therapeutics by 11.7% in the 1st quarter. Janus Henderson Group PLC now owns 2,734,836 shares of the company’s stock valued at $35,594,000 after buying an additional 285,857 shares in the last quarter. Finally, Royal Bank of Canada increased its position in Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after buying an additional 2,454 shares during the period.

Key Contineum Therapeutics News

Here are the key news stories impacting Contineum Therapeutics this week:

• Negative Sentiment: The MOONLIGHT-1 study did not demonstrate a statistically significant improvement versus placebo in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5, missing the trial’s primary endpoint. Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
• Negative Sentiment: Multiple reports linked the stock’s weakness to the failed MDD trial, increasing uncertainty around the development program and potentially reducing the value investors assign to Contineum’s pipeline. Update: Contineum Therapeutics Shares Fall After Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint
• Neutral Sentiment: JonesTrading lowered its price target from $26 to $24 but maintained a “buy” rating, while Robert W. Baird reduced its target from $20 to $19 and retained an “outperform” rating. The continued bullish ratings provide some support, although the target cuts reflect heightened risk after the trial result.
• Neutral Sentiment: Options activity surged, with investors purchasing 10,034 call contracts—far above the typical volume. This may indicate speculative optimism or positioning for volatility, but it does not by itself confirm a sustained bullish outlook.

Contineum Therapeutics Stock Down 6.7%

CTNM opened at $13.82 on Friday. Contineum Therapeutics has a 12-month low of $8.60 and a 12-month high of $17.78. The stock has a market cap of $519.91 million, a price-to-earnings ratio of -7.99 and a beta of 0.75. The business has a 50 day moving average of $15.35 and a 200-day moving average of $14.04.

Contineum Therapeutics (NASDAQ:CTNM) last posted its earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. As a group, analysts expect that Contineum Therapeutics will post -1.68 earnings per share for the current year.

About Contineum Therapeutics

Contineum Therapeutics, formerly known as Pipeline Therapeutics, is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for diseases of the central nervous system. The company’s research is aimed at promoting remyelination and neurorepair, processes that may restore damaged nerve function rather than solely managing disease symptoms.

Contineum’s lead programs include PIPE-307, an oral, brain-penetrant therapy designed to promote remyelination through selective inhibition of the M1 muscarinic receptor, and PIPE-791, an oral antagonist of the lysophosphatidic acid receptor 1.